ELLIS B. FREILICH, M.D.; GEORGE C. COE, M.D.; NORMAN A. WIEN, M.D.
This content is PDF only. Please click on the PDF icon to access.
The chemotherapeutic effects of sulfanilamide (para-amino-benzene sulfonamide) in certain infectious diseases have been successfully demonstrated in humans and in experimental animals. Although the best results have been obtained in beta hemolytic streptococcic infections, it has been used in other conditions, as gonococcic urethritis, meningococcus meningitis, colon bacillus pyelitis, brucellosis, etc., with varying degrees of success. Intensive studies have been carried out by Long and Bliss, who in a recent article1 give an excellent bibliography of investigations in this field.
However, the possible use of sulfanilamide in chronic granulomatous infections has so far received little if any attention. In January 1938
FREILICH EB, COE GC, WIEN NA. THE USE OF SULFANILAMIDE IN PULMONARY TUBERCULOSIS; PRELIMINARY REPORT1. Ann Intern Med. ;13:1042–1045. doi: 10.7326/0003-4819-13-6-1042
Download citation file:
Published: Ann Intern Med. 1939;13(6):1042-1045.
Infectious Disease, Mycobacterial Infections, Pulmonary Tuberculosis, Pulmonary/Critical Care.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use